Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status

被引：0
|
作者：
Jinghui Wang
Yujie Dong
Yiran Cai
Lijuan Zhou
Shafei Wu
Guimei Liu
Dan Su
Xi Li
Na Qin
Jingying Nong
Hongyan Jia
Quan Zhang
Jing Mu
Xuan Zeng
Haiqing Zhang
Shucai Zhang
Zongde Zhang
机构：
[1] Capital Medical University,Department of Medical Oncology, Beijing Thoracic Tumor and Tuberculosis Research Institute, Beijing Chest Hospital
[2] Capital Medical University,Department of Pathology, Beijing Thoracic Tumor and Tuberculosis Research Institute, Beijing Chest Hospital
[3] Chinese Academy of Medical Sciences,Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College
[4] Capital Medical University,Department of Radiotherapy, Beijing Thoracic Tumor and Tuberculosis Research Institute, Beijing Chest Hospital
[5] Capital Medical University,Department of Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Thoracic Tumor and Tuberculosis Research Institute, Beijing Chest Hospital
来源：
Journal of Cancer Research and Clinical Oncology | 2014年 / 140卷
关键词：
EGFR; KRAS; ALK; Lung adenocarcinoma; Fluorescent in situ hybridization;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：453 / 460
页数：7
相关论文
共 50 条
  • [1] Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status
    Wang, Jinghui
    Dong, Yujie
    Cai, Yiran
    Zhou, Lijuan
    Wu, Shafei
    Liu, Guimei
    Su, Dan
    Li, Xi
    Qin, Na
    Nong, Jingying
    Jia, Hongyan
    Zhang, Quan
    Mu, Jing
    Zeng, Xuan
    Zhang, Haiqing
    Zhang, Shucai
    Zhang, Zongde
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (03) : 453 - 460
  • [2] The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma
    Qu, Yang
    Che, Nanying
    Zhao, Dan
    Zhang, Chen
    Su, Dan
    Zhou, Lijuan
    Zhang, Lili
    Wang, Chongli
    Zhang, Haiqing
    Wei, Lixin
    TUMOR BIOLOGY, 2015, 36 (08) : 6417 - 6424
  • [3] Relationship of radiometabolic biomarkers to KRAS mutation status and ALK rearrangements in cases of lung adenocarcinoma
    Aras, Gulfidan
    Kanmaz, Zehra Dilek
    Tuncay, Esin
    Cetinkaya, Erdogan
    Yenturk, Esin
    Kocaturk, Celalettin
    Oz, Buge
    Cermik, Tevfik Fikret
    Purisa, Sevim
    TUMORI JOURNAL, 2019, 105 (06): : 501 - 508
  • [4] Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
    Lee, Boram
    Lee, Taebum
    Lee, Se-Hoon
    Choi, Yoon-La
    Han, Joungho
    ONCOTARGET, 2016, 7 (17) : 23874 - 23884
  • [5] Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
    Wu, Shafei
    Wang, Jinghui
    Zhou, Lijuan
    Su, Dan
    Liu, Yuanyuan
    Liang, Xiaolong
    Zhang, Shucai
    Zeng, Xuan
    THORACIC CANCER, 2015, 6 (04) : 413 - 420
  • [6] MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status
    Kim, Hyojin
    Yang, Jeong Mi
    Jin, Yan
    Jheon, Sanghoon
    Kim, Kwhanmien
    Lee, Choon Taek
    Chung, Jin-Haeng
    Paik, Jin Ho
    ONCOTARGET, 2017, 8 (05) : 8484 - 8498
  • [7] Genetic Associations of Visfatin Polymorphisms with EGFR Status and Clinicopathologic Characteristics in Lung Adenocarcinoma
    Chang, Sunny Li-Yun
    Yang, Po-Jen
    Lin, Yen-You
    Jiang, Ya-Jing
    Liu, Po-, I
    Huang, Chang-Lun
    Yang, Shun-Fa
    Tang, Chih-Hsin
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (22)
  • [8] Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma
    Hofman, P.
    Ilie, M.
    Hofman, V.
    Roux, S.
    Valent, A.
    Bernheim, A.
    Alifano, M.
    Leroy-Ladurie, F.
    Vaylet, F.
    Rouquette, I.
    Validire, P.
    Beau-Faller, M.
    Lacroix, L.
    Soria, J. C.
    Fouret, P.
    ANNALS OF ONCOLOGY, 2012, 23 (07) : 1738 - 1743
  • [9] Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
    Thomas, David
    Maloney, McKenzie E.
    Raval, Girindra
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [10] Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
    Brcic, Luka
    Jakopovic, Marko
    Misic, Marija
    Seiwerth, Fran
    Kern, Izidor
    Smojver-Jezek, Silvana
    Quehenberger, Franz
    Samarzija, Miroslav
    Seiwerth, Sven
    DIAGNOSTIC PATHOLOGY, 2016, 11 : 1
12345